New study aims to help people with disabilities suffering from uncontrollable movements
NCT ID NCT06997198
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times
Summary
This study tests a drug called deutetrabenazine for tardive dyskinesia (uncontrollable movements) in 25 adults with intellectual/developmental disabilities and psychiatric or behavioral disorders. Participants will take the medication for 24 weeks to see if it reduces movement problems and improves daily life. The goal is to find a safe and effective treatment for this group, who often have trouble with standard movement exams.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals of Cleveland
Cleveland, Ohio, 44106, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.